Pharma & Biotech Insights, Interviews & Features
Biotechnology
11 November 2024 11 November 2024
Today's issue
Refine Search
Pharmaceutical
The last quarter of 2020 saw the beginning of the roll-out of coronavirus vaccines in the quickest countries off the mark and saw some big biopharma M&A deals, most notably AstraZeneca's $39 billion buy of Alexion Pharmaceuticals. 18 January 2021
Biotechnology
Investors will continue to chase after Chinese biotechs despite obvious bubbles, said speakers from several venture capitals and biotechs at China Biomed innovation and investment conference held online on January 12, reports The Pharma Letter’s correspondent Wang Fangqing. 18 January 2021
Generics
Highlighting over-medication as a potential hazard while also flagging the prospect of 'profiteering' by drug companies, India's drug price watchdog the National Pharmaceutical Pricing Authority (NPPA) has expressed concern about the many drug cocktail applications that continue to flood its office as also those that are surreptitiously available in the country, reports The Pharma Letter’s India correspondent. 18 January 2021
Generics
In October 2020, the US Food and Drug Administration issued guidance for industry entitled “Referencing Approved Drug Products in Abbreviated New Drug Application (ANDA) Submissions.” 12 January 2021
Pharmaceutical
The authorities of St Petersburg, one of the main centers of pharmaceutical production in Russia, plan to create additional conditions to attract foreign drugmakers to the region, according to press-service of the St Petersburg regional government and local pharma analysts. 12 January 2021
Pharmaceutical
Russia continues to experience a shortage of at least 42 drugs, which are used for the treatment of some serious diseases including COVID-19, according to recent statements, by analysts of the All-Russian Union of Patients (VSP) and some local media, reports The Pharma Letter’s local correspondent. 12 January 2021
Pharmaceutical
As demand for the India-made COVID-19 vaccines gathers pace in foreign countries, even China seems to have grudgingly conceded that India's COVID-19 vaccines are good, reports The Pharma Letter’s local correspondent. 11 January 2021
Pharmaceutical
Rick Brar, chief executive at Brains Bioceutical, considers the implications of the UK’s departure from the European Union (EU) in an Expert View piece. 8 January 2021
Pharmaceutical
No company has been exclusively focused on neuroscience for as long as Lundbeck (CPH: LUN). 5 January 2021
Pharmaceutical
Leading Russian drugmakers, as well as global pharmaceutical producers, operating in Russia fear of the possible collapse of the local pharmaceutical market after February, 1 2021 – the date, when the simplified period of work of a drug labelling system ends, reports The Pharma Letter’s local correspondent. 5 January 2021
Biotechnology
Nearly the whole of 2020 was dominated by the impact of the novel coronavirus, but the global biopharmaceutical industry, apart from being instrumental in bringing to market treatments for the symptoms of COVID-19 as well as vaccines to prevent it, continued about its business in difficult times. 1 January 2021
Biotechnology
Registration of Russia’s first gene therapy drug Zolgensma (onasemnogene abeparvovec) for the treatment of spinal muscular atrophy (SMA), may be delayed by one and a half years as, in order to assess the quality of the drug, the Russian Ministry of Health has demanded from the Swiss pharma giant Novartis up to 40 vials with a total price of up to $88 million, reports The Pharma Letter’s local correspondent. 29 December 2020
Generics
Hyderabad, India-based Natco Pharma is seeking to file a compulsory licensing application for a generic version of Eli Lilly's arthritis drug baricitinib, in a move that could potentially lead to a legal battle over intellectual property rights (IPR), reports The Pharma Letter’s local correspondent. 23 December 2020
Pharmaceutical
The demand for foreign drugs designed for cancer treatment in Russia remains stable, despite the ever-growing number of generics in the local market, according to recent statements by some leading Russian pharma analysts and local media, reports The Pharma Letter’s local correspondent. 22 December 2020
Biosimilars
China-based Henlius, the biotech arm of Fosun Pharma’s, is likely to have a busy year ahead. 22 December 2020
Pharmaceutical
Phenylketonuria (PKU) is a rare autosomal recessive condition caused by mutations in the phenylalanine-4-hydroxylase (PAH) gene. This gene is involved in the production of the PAH enzyme. 18 December 2020
Pharmaceutical
The year 2020 has brought unprecedented scientific challenges for the US Food and Drug Administration as it joined the global battle against the COVID-19 pandemic. Despite the challenges faced, the FDA stands in a strong position, with robust scientific and regulatory processes in place to evaluate potential COVID-19 vaccines and drugs. 17 December 2020
Generics
India's Department of Pharmaceuticals (DoP) is in the midst of a second round of production-linked incentive (PLI) schemes to boost domestic manufacturing of excipients. Currently, India imports 95% of its requirements from regulated markets like the USA, Europe and China. With a five-member technical committee assisting the DoP for Phase II of the PLI scheme, India is keen to incentivize its excipient manufacturers, reports The Pharma Letter’s India correspondent. 15 December 2020
Pharmaceutical
UK pharma major AstraZeneca has announced the launch of full-cycle production of Forxiga (dapagliflozin), its drug designed for the treatment of adult patients with type 2 diabetes mellitus and chronic heart failure, in Russia at the facilities of its local plant in the Kaluga region, according to recent statements, made by the company and the regional authorities, reports The Pharma Letter’s local correspondent 15 December 2020
Pharmaceutical
As China rushes in with its COVID-19 shots, India is now in a race with China in making a locally-produced coronavirus vaccine accessible to the entire South Asian region, reports The Pharma Letter’s local correspondent. 11 December 2020
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze